Quantitative assessment of liver fibrosis (qFibrosis) reveals precise outcomes in Ishak “stable” patients on anti-HBV therapy
Yameng Sun(Renji Hospital), Hong You(Harbin Institute of Technology), Lungen Lu(Shanghai Jiao Tong University), Huiguo Ding(Capital Medical University), Jialing Zhou(Capital Medical University), Hui Liu(Capital Medical University), Neil D. Theise(New York University), Yuemin Nan(Hebei Medical University), Wei Jiang(Sun Yat-sen University), Hongxin Piao(Yanbian University Hospital), Xiaoning Wu(First Affiliated Hospital of Xi'an Jiaotong University), Tailing Wang(China-Japan Friendship Hospital), Aileen Wee(National University Hospital), Jidong Jia(National Clinical Research Center for Digestive Diseases), Xiaojuan Ou(Capital Medical University), Yongpeng Chen(Guangxi University of Science and Technology)
Cited by 43
Related Papers
aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis
|Journal of Hepatology|2020|346
New classification of liver biopsy assessment for fibrosis in chronic hepatitis B patients before and after treatment
|Hepatology|2016|156
CDC42 and Rac1 are implicated in the activation of the Nef-associated kinase and replication of HIV-1
|Current Biology|1996|138
Global burden of liver cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2019
|BMC Public Health|2024|123
Persistent Low Level of Hepatitis B Virus Promotes Fibrosis Progression During Therapy
|Clinical Gastroenterology and Hepatology|2020|115